Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents enhance insulin production and suppress glucagon se… Read More

Retaglutide and tirzepatide represent innovative class of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones… Read More